A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it is associated with cardiotoxicity, especially in older patients. Substituting doxorubicin with non-PEGylate...

Descripción completa

Detalles Bibliográficos
Autores principales: Arcari, Annalisa, Rigacci, Lugi, Tucci, Alessandra, Puccini, Benedetta, Usai, Sara Veronica, Cavallo, Federica, Fabbri, Alberto, Balzarotti, Monica, Pelliccia, Sabrina, Luminari, Stefano, Pennese, Elsa, Zilioli, Vittorio Ruggero, Mahmoud, Abdurraouf Mokhtar, Musuraca, Gerardo, Marino, Dario, Sartori, Roberto, Botto, Barbara, Gini, Guido, Zanni, Manuela, Hohaus, Stefan, Tarantini, Giuseppe, Flenghi, Leonardo, Tani, Monica, Di Rocco, Alice, Merli, Michele, Vallisa, Daniele, Pagani, Chiara, Nassi, Luca, Dessì, Daniela, Ferrero, Simone, Cencini, Emanuele, Bernuzzi, Patrizia, Mammi, Caterina, Marcheselli, Luigi, Tabanelli, Valentina, Spina, Michele, Merli, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407138/
https://www.ncbi.nlm.nih.gov/pubmed/37276080
http://dx.doi.org/10.1182/bloodadvances.2023009839

Ejemplares similares

Ejemplares similares